Background
In 2019, it is estimated that 7200 Canadians (4700 men and 2500 women) will be diagnosed with kidney and renal pelvis cancer, and that 1900 Canadians will die from kidney and renal pelvis cancer. In Alberta, 680 new kidney cancer diagnoses are anticipated in 2019.
Renal cell carcinoma (RCC) is the main focus of this guideline. The most common subtype of renal cell carcinoma is clear cell RCC, followed by papillary and chromophobe tumours. Staging of renal cell carcinoma is currently based on the 8th edition (2017) of the American Joint Committee on Cancer's AJCC Cancer Staging Manual (see Appendix).
Guideline Questions 1. What are the appropriate diagnostic tests for renal cell carcinoma? 2. How should renal cell carcinoma be managed (i.e., surgically)? 3. What is the role of systemic therapy and radiotherapy in the management of renal cell carcinoma? 4. Are there other therapies that have shown benefit for patients with renal cell carcinoma? 5. What are the appropriate follow up strategies for renal cell carcinoma?
Search Strategy
Phase III trials involving 'renal cell carcinoma' that had been published since the last iteration of the guideline were identified and reviewed using the pubmed database. The results of the literature review are available upon request (guru@ahs.ca).
o CXR o CT scan of abdomen/pelvis with contract (or MRI) o CBC, Creatinine, calcium, liver function tests (LFTs) o Biopsy is an option as part of active observation or prior to ablative therapy o Optional Tests:
 CT chest if T2 or T3  Bone scan if T2 or T3 or alkaline phosphatase is elevated
• First-line Therapy: o Active surveillance is a reasonable option for T1a disease in elderly or medically comprised patients:  Biopsy an option initially.  Repeat imaging every 6 months.  Intervention is indicated if there is progression. o Surgical intervention 1, 2  Partial nephrectomy should be considered in all cases where surgery is being considered especially in T1 lesions. This can be done either as an open, laparoscopic, or assisted laparoscopic procedure.  If a partial nephrectomy is not feasible, consider a laparoscopic/robotic nephrectomy.  If the laparoscopic or robotic procedures cannot be performed then an open nephrectomy should be done.  Wherever possible the adrenal gland should not be removed unless involved on imaging. o Minimally invasive therapy  Both radiofrequency ablation (RFA) and cryoablation are suitable treatments for primarily T1a RCC with urologic consultation [3] [4] [5] [6] [7] [8] [9] . The treatment decision is only to be made after this consultation. This will ensure appropriate follow up is instituted. Cryoablation: percutaneous (or laparoscopic); T1 size 2-5.5 cm Radiofrequency ablation: peripheral tumours size 2-4 cm (T1a)
Follow-up
Follow up is based on the recommendations of the Canadian Urological Association (CUA) as published on the CUA website (http://www.cua.org/) and the CUA Journal (CUAJ) in 2009 10 , and is stage dependent: 
If relapses are to occur, they may happen early or very late. Therefore, the necessary duration of follow-up beyond these guidelines is unclear and should be directed based on relapse risk.
Stage T4, N1-2, M+ 11
Indications include locally advanced, unresectable cancer or metastatic disease. 
Discussion

Early Stage Disease
For patients with early stage node negative disease, options for first-line therapy include partial nephrectomy, active surveillance or minimally invasive therapy with cryoablation or radiofrequency ablation. Active surveillance is best suited for individuals with T1a lesions, who are elderly or medically compromised. In these patients, a biopsy should be performed initially, followed by repeat imaging every six months with intervention upon progression. Cryoablation and radiofrequency ablation are also primarily for patients with T1a disease (only after consultation with an urologist, to ensure appropriate follow-up). Both are excellent treatment options for early stage disease, with longterm disease free survival rates ranging from 92 to 98%. [3] [4] [5] [6] [7] [8] A retrospective study among patients with renal cell carcinoma who underwent percutaneous CT-guided radiofrequency ablation (n=41) or cryoablation (n=70) demonstrated equivalent imaging (e.g. MRI) recurrence rates (11% vs. 7%, respectively; p=.60). 9 In medically fit patients, including those that are elderly, partial nephrectomy is an excellent option. In an analysis of the SEER database, among patients with T1aN0M0 renal cell carcinoma (n=7,280), cancer-specific mortality for partial-and radical-nephrectomy were 1.8% and 2.5%, respectively (p=.5) for all patients and 1.0% and 3.4% (p=0.7), respectively, for patients aged 70 years and over. 1 
Advanced Stage Disease
For patients with advanced, node positive, and/or unresectable or metastatic disease, systemic therapy is indicated.
First-line Therapy:
The combination of ipilimumab and nivolumab (ipi/nivo) compared to sunitinib alone was studied in the CHECKMATE 214 study. 29 In the extended follow up (32 months) analyses, 68 In 2019, the KEYNOTE-426 study examined the combination of pembrolizumab and axitinib (pembrolizumab/axitinib) compared to sunitinib alone. 66 Sunitinib and pazopanib may be treatment options first line, but the options mentioned above have demonstrated their superiority to sunitinib. Historically, Temsirolimus is another option for first-line therapy, especially in poor-risk patients. 30, 45 However, this combination is rarely used now because of the availability of other more efficacious treatment options detailed above.
After First-line Therapy:
Nivolumab (PD-1 Inhibitor): The CheckMate 025 trial demonstrated an overall survival benefit of nivolumab compared to everolimus with fewer grade 3 or 4 adverse events in patients already treated with one or two targeted therapies. 36, 38 Median OS was 25.0 months in the nivolumab arm vs. 19.6 months in the everolimus arm (N=821). Median PFS was 4.6 months with nivolumab and 4.4 months with everolimus. Grade 3/4 treatment-related adverse events occurred in 19% of nivolumab patients and 37% of everolimus patients. 38 Axitinib is a selective second-generation inhibitor of VEGF receptors. It has shown positive results in a phase III trial compared with sorafenib. The 723 patients included in the study had confirmed renal cell carcinoma that progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Median PFS was 6.7 months for axitinib versus 4.7 months in patients receiving sorafenib, with non-significant differences regarding toxicity. 42 Cabozantinib (VEGF/Met inhibitor): The METEOR trial has reported PFS benefit and an OS benefit for cabozantinib when compared to everolimus in patients that progressed after VEGFR-targeted therapy. 39 Median PFS was 7.4 months with cabozantinib and 3.8 months with everolimus (p<0.001) and the objective response rate was higher with cabozantinib (21% vs 5% with everolimus; p<0.001). OS was longer with cabozantinib when compared to everolimus HR 0.66 (95%CI: 0.53-0.83). 40 Adverse events were managed with dose reduction; dose reduction occurred in 60% of patients who received cabozantinib (vs. 25% in those on everolimus), and discontinuation of treatment due to adverse events occurred in 9% of patients who received cabozantinib (vs. 10 in those on everolimus).
Historically, everolimus and sorafenib were considered as treatment options but these are now superseded by the options discussed above. Although everolimus and sorafenib are funded treatment options, their use is uncommon because the above agents have demonstrated superiority to everolimus.
The appropriate sequencing of these agents after first-line therapy is unknown. The current recommended treatment options in Alberta are shown in figure 2. Third-and fourth-line regimens would use drugs not previously used in the patient.
Figure 2. Recommended Treatment Sequences for mRCC in Alberta*
Local Therapy:
Prior to 2018, there is little data to guide clinical practice in relation to cytoreductive nephrectomy (CN) in the era of targeted therapy and decisions are made based on clinical indications. In phase III trials, the majority of patients had undergone a nephrectomy prior to systemic therapy. 16, 50, 57 Nephrectomy has proven overall survival benefit when used in conjunction with interferon. 58, 59 Among patients treated with interferon alfa-2a (n=159), univariate and multivariate statistical analyses showed that prior nephrectomy was a significant prognostic factor for survival. 59 A prospective trial also showed that among patients with metastatic renal-cell cancer who were acceptable candidates for nephrectomy (n=120), the addition of interferon alfa-2b resulted in prolonged median survival (11.1 vs. 8.1 months, interferon alone; p=.05). 58, 59 Patients who appear to benefit most from nephrectomy are those with most of the tumour burden within the kidney, good performance status, and no central nervous or liver involvement (with rare exceptions). 58, 59 Other considerations include surgical resectability, including possible morbidity to proximal vital structures, encasement of the renal hilum and other complicating factors. 54, 55 Laparoscopic nephrectomy is the emerging standard surgical procedure and should be considered whenever technically feasible. 60, 61 The phase III CARMENA trial was published in 2018 and it randomized patients to CN with sunitinib versus sunitinib alone. 53 It demonstrated that sunitinib alone was non-inferior to the CN arm. It should be noted that over 40% of patients enrolled had poor-risk disease so the typical CN patient may not have been included in this trial. Thus, there remain patients that are still eligible for CN including patients with limited metastatic disease with large primary tumours and those with symptomatic primary tumours. A retrospective series of 198 patients presented at GU ASCO 2020 showed that CN was associated with improved survival for patients with metastatic renal cell carcinoma treated with immunotherapy. 62 However, there is no prospective data on CN with first line checkpoint inhibitor combinations. Currently, upfront CN should be considered in the following clinical scenarios: 63 1 Lastly, nephrectomy or renal embolization (when nephrectomy is not possible) can also be offered as palliative procedures at any time when clinically indicated.
Adjuvant Therapy:
Currently, there is no role for adjuvant therapy in localized, resected renal cell carcinoma. The adjuvant ASSURE trial randomized patients between sunitinib, sorafenib and placebo and did not demonstrate any benefit. 64 The S-TRAC trial randomized higher risk clear cell patients to one year of sunitinib versus placebo. 65 There was a difference in disease free survival however the overall survival data were immature and there was no difference. Additionally, the PROTECT clinical trial of adjuvant pazopanib vs placebo was negative for the primary endpoint. Also the phase III ATLAS trial evaluating axitinib as adjuvant therapy for patients at high risk of recurrent RCC after nephrectomy was halted after interim analysis due to futility. 66 We are awaiting the results of other adjuvant clinical trials before we can recommend adjuvant therapy routinely in this setting. Enrollment of these patients into a clinical trial is encouraged. 
Cancer Staging Manual (American Joint Committee on Cancer, 8th edition 2017)
Primary Tumour (T) TX: Primary tumor not evaluated.
T1:
The tumor is found only in the kidney and is 7 centimeters (cm) or smaller at its largest area.
T1a: The tumor is found only in the kidney and is 4 cm or smaller at its largest area. T1b: The tumor is found only in the kidney and is between 4 cm and 7 cm at its largest area.
T2:
The tumor is found only in the kidney and is larger than 7 cm at its largest area. T2a: The tumor is only in the kidney and is more than 7 cm but not more than 10 cm at its largest area. T2b: The tumor is only in the kidney and is more than 10 cm at its largest area.
T3:
The tumor has grown into major veins within the kidney or perinephric tissue. However, it has not grown into the adrenal gland on the same side of the body as the tumor. T3a: The tumor extends into renal vein or segmental branches. T3b: The tumour extends into the vena cava below the diaphragm. T3c: The tumour extends into the vena cava above the diaphragm.
T4: Direct invasion into the adrenal gland.
Regional Lymph Nodes (N) NX: Regional lymph nodes not evaluated. N0: The cancer has not spread to the regional lymph nodes. N1: The cancer has spread to regional lymph nodes Distant Metastasis (M) M0: The disease has not metastasized.
M1:
The cancer has spread to other parts of the body beyond the kidney area. T  N  M  I  T1  N0  M0  II  T2  N0  M0  III  T1-2  N1  M0  T3 NX, N0, or N1 M0 IV T4 Any N M0 Any T Any N M1
Stage
